Overview
-

1trillion(KRW)
- The total export value of Remsima®
- In October 2016, Remsima®'s total export value reached reached KRW 1 trillion(the Korea International Trade Association).
-

32countries
- Number of overseas subsidiaries
- The number of countries with Celltrion Healthcare’s overseas subsidiaries(2019).
-

38partners
- Number of global partners
- Global partners in charge of the biologics’ distribution along with Celltrion Healthcare(2019).
-

52%
- Remsima®'s market share
bypassing that of the orginator
- Remsima® is the first mAb biosimilar to bypass the originator's market share in Europe (2017).
-

110countries
- Sales market
- The number of countries where Celltrion Healthcare’s core biosimilars are available for purchase(and officially approved, 2019).
-

1trillion(KRW)
- The annual value of Remsima®
prescribed in the world
- For the first time as a Korean medication,
the annual value of Remsima® prescribed across the world reached KRW 1 trillion (2018).